Trial Profile
A Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Therapeutic Effect of Topical BPM31510 3.0% Cream in Patients With Epidermolysis Bullosa
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Jun 2020
Price :
$35
*
At a glance
- Drugs Ubidecarenone (Primary)
- Indications Epidermolysis bullosa
- Focus Adverse reactions
- 14 Jun 2020 Status changed from active, no longer recruiting to completed.
- 19 Jan 2020 Planned End Date changed from 1 Jan 2020 to 1 Jul 2020.
- 08 Jul 2019 Status changed from recruiting to active, no longer recruiting.